A detailed history of Meritage Portfolio Management transactions in United Therapeutics Corp stock. As of the latest transaction made, Meritage Portfolio Management holds 1,289 shares of UTHR stock, worth $487,409. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,289
Previous 1,176 9.61%
Holding current value
$487,409
Previous $375,000 23.2%
% of portfolio
0.03%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$311.04 - $363.55 $35,147 - $41,081
113 Added 9.61%
1,289 $462,000
Q2 2024

Aug 08, 2024

SELL
$228.26 - $319.04 $228 - $319
-1 Reduced 0.08%
1,176 $375,000
Q1 2024

Apr 29, 2024

SELL
$210.76 - $249.51 $14,542 - $17,216
-69 Reduced 5.54%
1,177 $270,000
Q4 2023

Feb 02, 2024

BUY
$214.88 - $256.94 $4,512 - $5,395
21 Added 1.71%
1,246 $274,000
Q3 2023

Oct 30, 2023

SELL
$211.82 - $248.24 $8,684 - $10,177
-41 Reduced 3.24%
1,225 $277,000
Q2 2023

Jul 31, 2023

BUY
$205.19 - $232.99 $42,474 - $48,228
207 Added 19.55%
1,266 $279,000
Q1 2023

Apr 25, 2023

SELL
$212.99 - $276.17 $7,667 - $9,942
-36 Reduced 3.29%
1,059 $237,000
Q4 2022

Feb 01, 2023

BUY
$205.95 - $280.43 $7,620 - $10,375
37 Added 3.5%
1,095 $305,000
Q3 2022

Oct 25, 2022

BUY
$203.3 - $244.17 $1,219 - $1,465
6 Added 0.57%
1,058 $222,000
Q2 2022

Jul 25, 2022

BUY
$174.81 - $241.14 $183,900 - $253,679
1,052 New
1,052 $248,000
Q1 2022

Apr 25, 2022

SELL
$166.16 - $213.96 $157,187 - $202,406
-946 Closed
0 $0
Q4 2021

Jan 28, 2022

BUY
$184.32 - $216.08 $174,366 - $204,411
946 New
946 $204,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17.2B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Meritage Portfolio Management Portfolio

Follow Meritage Portfolio Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meritage Portfolio Management, based on Form 13F filings with the SEC.

News

Stay updated on Meritage Portfolio Management with notifications on news.